To study Shatapushpa Churna effects in animal study & in patients of Polycystic Ovarian Syndrome.
Not Applicable
- Conditions
- Health Condition 1: E282- Polycystic ovarian syndrome
- Registration Number
- CTRI/2022/01/039331
- Lead Sponsor
- DrRutuja SGaikwad
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
All married & unmarried cases
-USG with polycystic ovaries showing multiple small peripheral follicles( >12 follicles)in each ovary measuring 2-9mm in diameter and/or increased ovarian volume >10mm.
-All cases of PCOS having amenorrhoea/oligomenorrhoea.
-PCOS patients having signs of hyperandrogenism
Exclusion Criteria
-Amenorrhoea of menopause
-Patients of PCOS with DM/HTN/Hypothyroidism/Hyperthyroidism/TB/HIV/HbSAg/VDRL
-Cases of prgnancy,cervical tumor/polyp, uterine fibroid
-known cases of systemic illness like asthma,cardiovascular and renal diseases,malignancy, Salpingo oophoritis, Cervical erosion, anatomical defective genitalia
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method -To observe the histopathological changes & steroidogenic enzyme activity in ovary in the Laterozole induced PCOS rat animal after administration of Shatapushpa churna <br/ ><br>-To evaluate the ovulatory effects of Shatapushpa churna in Latrazole induced PCOS in rat animal <br/ ><br>-To study the clinical action of Shatapushpa Churna in PCOS by assessing ovulatory effects ,reduction in ovarion volume and status of menstruation.Timepoint: 9 MONTHS
- Secondary Outcome Measures
Name Time Method -To evaluate the effects of Shatapushpa churna in PCOS by assessing the changes in biochemical markers like FSH LH E2 TESTOSTERON DHEAS GTT SERUM LIPID PROFILE SERUM INSULIN LEVEL <br/ ><br>-To assess the effect of Shatapushpa churna in Achanthosis Nigrans Hirsutism AcneTimepoint: 9 MONTHS